Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective Randomised Phase III Trial to Evaluate Optimal Treatment Duration of First-line Bevacizumab in Combination With Carboplatin and Paclitaxel in Patients With Primary Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
Brief Summary: The purpose of this study is to determine whether the early and continuous addition of bevacizumab for up to 30 months to the standard chemotherapy is more effective than the early and continuous addition of bevacizumab for up to 15 months.


Options:
A: Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): N/A
B: Arm Label: Carboplatin + Paclitaxel + Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Drug: Bevacizumab | Arm Label: Carboplatin + Paclitaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Drug: Bevacizumab | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Carboplatin + Paclitaxel, Carboplatin + Paclitaxel + Bevacizumab | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Carboplatin + Paclitaxel, Carboplatin + Paclitaxel + Bevacizumab | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Carboplatin + Paclitaxel, Carboplatin + Paclitaxel + Bevacizumab
C: Arm Label: Control Arm; Type: OTHER; Interventions: Biological: Bevacizumab, Drug: Paclitaxel, Drug: Carboplatin, Other: specialized pathology review (Germany only) | Arm Label: Research Arm; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel, Drug: Carboplatin, Other: specialized pathology review (Germany only) | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Control Arm | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Control Arm, Research Arm | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Control Arm, Research Arm | Intervention Type: OTHER; Name: specialized pathology review (Germany only); Assigned to Arm(s): Control Arm, Research Arm
D: Arm Label: Arm I (placebo, paclitaxel, carboplatin); Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Other: Placebo, Other: Quality-of-Life Assessment | Arm Label: Arm II (placebo, paclitaxel, carboplatin, bevacizumab); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Carboplatin, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Other: Placebo, Other: Quality-of-Life Assessment | Arm Label: Arm III (paclitaxel, carboplatin, bevacizumab); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Carboplatin, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Other: Quality-of-Life Assessment | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Arm II (placebo, paclitaxel, carboplatin, bevacizumab), Arm III (paclitaxel, carboplatin, bevacizumab) | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm I (placebo, paclitaxel, carboplatin), Arm II (placebo, paclitaxel, carboplatin, bevacizumab), Arm III (paclitaxel, carboplatin, bevacizumab) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (placebo, paclitaxel, carboplatin), Arm II (placebo, paclitaxel, carboplatin, bevacizumab), Arm III (paclitaxel, carboplatin, bevacizumab) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm I (placebo, paclitaxel, carboplatin), Arm II (placebo, paclitaxel, carboplatin, bevacizumab), Arm III (paclitaxel, carboplatin, bevacizumab) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm I (placebo, paclitaxel, carboplatin), Arm II (placebo, paclitaxel, carboplatin, bevacizumab) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm I (placebo, paclitaxel, carboplatin), Arm II (placebo, paclitaxel, carboplatin, bevacizumab), Arm III (paclitaxel, carboplatin, bevacizumab)

Answer: C